[Translation] A randomized, controlled, open-label, phase Ib/III clinical study to evaluate the efficacy and safety of HJ891 combined with toripalimab in the treatment of first-line non-squamous non-small cell lung cancer with KRAS G12C mutation
剂量递增阶段,评价 HJ891 联合特瑞普利单抗治疗经一线及以上标准治疗失败的 KRAS G12C 突变的晚期非鳞非小细胞肺癌受试者的安全性及耐受性;剂量扩展阶段,评价 HJ891 联合特瑞普利单抗治疗一线 KRAS G12C突变的晚期非鳞非小细胞肺癌受试者的安全性及耐受性;选择HJ891联合特瑞普利单抗的Ⅲ期推荐给药剂量;
[Translation] In the dose escalation phase, the safety and tolerability of HJ891 combined with toripalimab in the treatment of subjects with advanced non-squamous non-small cell lung cancer with KRAS G12C mutation who have failed first-line standard treatment or above will be evaluated; in the dose expansion phase, the safety and tolerability of HJ891 combined with toripalimab in the treatment of subjects with advanced non-squamous non-small cell lung cancer with first-line KRAS G12C mutation will be evaluated; and the recommended Phase III dose of HJ891 combined with toripalimab will be selected;